A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer
The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.
Metastatic Colorectal Cancer
DRUG: SC0191|DRUG: SC0191 + Bevacizumab|DRUG: SC0191 + 5-FU/LV
Objective Response Rate, 12 months|Incidence and Severity of Dose Limiting Toxicities (DLTs), 12 months
The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.